Active	Status	Sponsor type	Region	Phase	Filter
3 Active 6 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Illerhaus, Gerald
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
OptiMATe, NCT04931368 / 2018-002115-96: De-escalated Induction Treatment in Primary CNS Lymphoma	Recruiting	3	326	Europe	Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix, Control intervention: four courses of MATRix	Klinikum Stuttgart, German Federal Ministry of Education and Research, University Hospital Freiburg	Primary Central Nervous System Lymphoma	08/27	05/28
MTR², NCT05583071: Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients with PCNSL	Recruiting	2	20	Europe	Tafasitamab, Lenalidomide, Rituximab, Methotrexate	University of Cologne, Incyte Corporation	Non-Hodgkin Lymphoma	02/27	04/27